Display options
Cite
Beckmann L, Künstner A, Freschi ML, et al. Telmisartan induces a specific gut microbiota signature which may mediate its antiobesity effect. Pharmacol Res. 2021;170:105724doi: 10.1016/j.phrs.2021.105724.
Beckmann, L., Künstner, A., Freschi, M. L., Huber, G., Stölting, I., Ibrahim, S. M., Hirose, M., Freitag, M., Langan, E. A., Matschl, U., Galuska, C. E., Fuchs, B., Knobloch, J. K., Busch, H., & Raasch, W. (2021). Telmisartan induces a specific gut microbiota signature which may mediate its antiobesity effect. Pharmacological research, 170105724. https://doi.org/10.1016/j.phrs.2021.105724
Beckmann, Laura, et al. "Telmisartan induces a specific gut microbiota signature which may mediate its antiobesity effect." Pharmacological research vol. 170 (2021): 105724. doi: https://doi.org/10.1016/j.phrs.2021.105724
Beckmann L, Künstner A, Freschi ML, Huber G, Stölting I, Ibrahim SM, Hirose M, Freitag M, Langan EA, Matschl U, Galuska CE, Fuchs B, Knobloch JK, Busch H, Raasch W. Telmisartan induces a specific gut microbiota signature which may mediate its antiobesity effect. Pharmacol Res. 2021 Aug;170:105724. doi: 10.1016/j.phrs.2021.105724. Epub 2021 Jun 09. PMID: 34116209.
Copy Download .nbib Format: NLM
Share it on

Pharmacol Res. 2021 Aug;170:105724. doi: 10.1016/j.phrs.2021.105724. Epub 2021 Jun 09.

Telmisartan induces a specific gut microbiota signature which may mediate its antiobesity effect.

Pharmacological research

Laura Beckmann, Axel Künstner, Marco L Freschi, Gianna Huber, Ines Stölting, Saleh M Ibrahim, Misa Hirose, Miriam Freitag, Ewan A Langan, Urte Matschl, Christina E Galuska, Beate Fuchs, Johannes K Knobloch, Hauke Busch, Walter Raasch

Affiliations

  1. Institute of Experimental and Clinical Pharmacology and Toxicology, University of Lübeck, Germany.
  2. Medical Systems Biology Group, Institute of Experimental Dermatology, University of Lübeck, Germany; Institute for Cardiogenetic, University of Lübeck, Germany.
  3. Institute of Experimental and Clinical Pharmacology and Toxicology, University of Lübeck, Germany; DZHK (German Centre for Cardiovascular Research), Partner Site Hamburg/Kiel/Lübeck, Lübeck, Germany; CBBM (Center of Brain, Behavior and Metabolism), Germany.
  4. Institute of Experimental Dermatology, University of Lübeck, Germany.
  5. Departement of Dermatology, University of Lübeck, Germany.
  6. Departement of Dermatology, University of Lübeck, Germany; Dermatological Sciences, University of Manchester, UK.
  7. Department Virus Immunology, Heinrich Pette Institute, Leibniz Institute for Experimental Virology, Hamburg, Germany.
  8. Leibniz Institute for Farm Animal Biology (FBN) Core Facility Metabolomics, Germany.
  9. Clinic of Infectiology and Microbiology, University Clinic Schleswig-Holstein, Campus Lübeck, Germany; DZHK (German Centre for Cardiovascular Research), Partner Site Hamburg/Kiel/Lübeck, Lübeck, Germany; Insitute for Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  10. Institute of Experimental and Clinical Pharmacology and Toxicology, University of Lübeck, Germany; DZHK (German Centre for Cardiovascular Research), Partner Site Hamburg/Kiel/Lübeck, Lübeck, Germany; CBBM (Center of Brain, Behavior and Metabolism), Germany. Electronic address: [email protected].

PMID: 34116209 DOI: 10.1016/j.phrs.2021.105724

Abstract

Telmisartan prevents diet-induced obesity (DIO) in rodents. Given that the precise underlying mechanism is not known, we examined whether a gut-related mechanism might be involved. Sprague-Dawley rats received cafeteria diet (CD) for 3 months to develop DIO and were administered either telmisartan (8 mg/kg

Copyright © 2021 Elsevier Ltd. All rights reserved.

Keywords: AT1-receptor antagonist; Gut microbiota; Obesity; Telmisartan

Publication Types